Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.780
-0.060 (-2.11%)
At close: Feb 21, 2025, 4:00 PM
2.870
+0.090 (3.24%)
After-hours: Feb 21, 2025, 7:55 PM EST
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $369.00K in the quarter ending September 30, 2024, with 33.70% growth. This brings the company's revenue in the last twelve months to $1.56M, down -351.13% year-over-year. In the year 2023, Perspective Therapeutics had annual revenue of $1.43M, down -73.52%.
Revenue (ttm)
$1.56M
Revenue Growth
-351.13%
P/S Ratio
95.27
Revenue / Employee
$13,084
Employees
119
Market Cap
186.54M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CATX News
- 1 day ago - Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - GlobeNewsWire
- 17 days ago - Perspective Therapeutics to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 6 weeks ago - Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM - Seeking Alpha
- 2 months ago - Perspective Therapeutics: Definitely Not Looking Overvalued Now - Seeking Alpha
- 3 months ago - Perspective Therapeutics to Participate in Upcoming Investor Conferences in December - GlobeNewsWire
- 3 months ago - Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium - GlobeNewsWire